TherapeuticsMD, Inc.: Stock Promotions, Insider Sales, And A Lock-Up Expiration Create 50% Downside
- TherapeuticsMD, Inc. rose 300% since last fall, despite a lack of a legitimate, underlying fundamental reason.
- At a fully diluted market cap over $800M, TXMD is extremely overvalued and should see a steep decline from here.
- There has been significant insider selling recently, and there is a high likelihood of more selling in the near future.
- As seen with other companies recently, the move coincided with the stock being promoted by individuals/companies that they "do business with".